Back to search

Article

IMPACT - Phase Ib Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

2025-12-02

Abstract excerpt

<h4>Purpose</h4> To evaluate safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. <h4>Patients and Methods</h4> In this Phase I trial, 12 patients with advanced melanoma (n=9) or renal cell carcinoma (n=3) who could no longer access further standard treatments received intramuscular neoantigen SLP vaccines wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
917b375c-f73f-5162-a9c7-a0f8e09721d3
DOI
10.64898/2025.12.02.25341434
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
IMPACT - Phase Ib Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell CarcinomaDOI 10.64898/2025.12.02.25341434
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.Semantic proximity
Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).Semantic proximity
An immunogenic personal neoantigen vaccine for patients with melanoma.Semantic proximity
A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor ChallengeSemantic proximity
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesSemantic proximity
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineSemantic proximity
Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitopeSemantic proximity
A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity
Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma modelSemantic proximity
Select a neighboring publication to make it the new centre.